Latest news with #Atea
Yahoo
4 days ago
- Business
- Yahoo
European Market Gems: Stocks Trading Below Estimated Value In June 2025
Amidst a backdrop of easing inflation and potential interest rate cuts by the European Central Bank, the European markets have shown resilience with indices like Germany's DAX and Italy's FTSE MIB posting gains. In such an environment, identifying stocks that are trading below their estimated value can present unique opportunities for investors seeking to capitalize on market inefficiencies. Name Current Price Fair Value (Est) Discount (Est) Micro Systemation (OM:MSAB B) SEK48.30 SEK95.13 49.2% CTT Systems (OM:CTT) SEK208.00 SEK406.70 48.9% Absolent Air Care Group (OM:ABSO) SEK211.00 SEK416.98 49.4% Sparebank 68° Nord (OB:SB68) NOK179.40 NOK358.38 49.9% USU Software (HMSE:OSP2) €25.485 €50.83 49.9% Vestas Wind Systems (CPSE:VWS) DKK106.20 DKK209.54 49.3% Montana Aerospace (SWX:AERO) CHF19.72 CHF38.66 49% doValue (BIT:DOV) €2.31 €4.50 48.7% 3U Holding (XTRA:UUU) €1.495 €2.99 49.9% VIGO Photonics (WSE:VGO) PLN526.00 PLN1024.74 48.7% Click here to see the full list of 182 stocks from our Undervalued European Stocks Based On Cash Flows screener. Let's explore several standout options from the results in the screener. Overview: Atea ASA offers IT infrastructure and related solutions to businesses and public sector organizations across the Nordic countries and Baltic regions, with a market cap of NOK16.73 billion. Operations: The company's revenue segments are comprised of NOK9 billion from Norway, NOK13.06 billion from Sweden, NOK8.25 billion from Denmark, NOK3.57 billion from Finland, and NOK1.80 billion from the Baltics, with Group Shared Services contributing an additional NOK10.81 billion. Estimated Discount To Fair Value: 39.7% Atea is trading at NOK 150.2, significantly below its estimated fair value of NOK 249, suggesting it may be undervalued based on cash flows. The company's revenue and earnings are forecast to grow faster than the Norwegian market, with earnings expected to rise by 19.7% annually. Despite a dividend yield of 4.66%, it's not well covered by earnings, raising sustainability concerns. Recent Q1 results showed increased sales but a decline in net income year-over-year. Our expertly prepared growth report on Atea implies its future financial outlook may be stronger than recent results. Take a closer look at Atea's balance sheet health here in our report. Overview: Hoist Finance AB (publ) is a credit market company involved in loan acquisition and management across Europe, with a market cap of SEK8.36 billion. Operations: The company's revenue segments consist of SEK1.16 billion from secured loans and SEK2.99 billion from unsecured loans. Estimated Discount To Fair Value: 19.6% Hoist Finance is trading at SEK 95.65, below its fair value estimate of SEK 119.04, reflecting potential undervaluation based on cash flows. While earnings grew by 34.6% last year and are forecast to grow significantly over the next three years, revenue growth is slower than ideal but still outpaces the Swedish market average. The company has a high debt level and a recent dividend approval of SEK 2 per share, though its dividend track record remains unstable. Our earnings growth report unveils the potential for significant increases in Hoist Finance's future results. Unlock comprehensive insights into our analysis of Hoist Finance stock in this financial health report. Overview: LEM Holding SA, along with its subsidiaries, offers solutions for measuring electrical parameters across various regions including China, Japan, South Korea, India, Southeast Asia, Europe, the Middle East, Africa, NAFTA and Latin America; the company has a market cap of CHF894.82 million. Operations: The company's revenue is primarily derived from two segments: Asia, contributing CHF168.27 million, and Europe/Americas, contributing CHF138.66 million. Estimated Discount To Fair Value: 24.5% LEM Holding is trading at CHF 786, below its estimated fair value of CHF 1040.42, suggesting undervaluation based on cash flows. Despite a challenging year with net income dropping to CHF 8.39 million from CHF 65.33 million, earnings are forecast to grow significantly at 48% annually over the next three years, outpacing the Swiss market average. However, profit margins have decreased and the company carries a high level of debt. Upon reviewing our latest growth report, LEM Holding's projected financial performance appears quite optimistic. Click here to discover the nuances of LEM Holding with our detailed financial health report. Access the full spectrum of 182 Undervalued European Stocks Based On Cash Flows by clicking on this link. Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools. Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include OB:ATEA OM:HOFI and SWX:LEHN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
3 European Growth Companies With Up To 34% Insider Ownership
As the European markets navigate through a period of trade negotiations and slowing inflation, indices such as the STOXX Europe 600 have shown resilience with modest gains. In this environment, growth companies with substantial insider ownership can be particularly appealing, as they often indicate strong confidence from those closest to the company's operations and strategy. Name Insider Ownership Earnings Growth Xbrane Biopharma (OM:XBRANE) 21.8% 56.8% Pharma Mar (BME:PHM) 11.8% 44.9% MedinCell (ENXTPA:MEDCL) 13.9% 85.7% Lokotech Group (OB:LOKO) 4.4% 58.1% KebNi (OM:KEBNI B) 38.3% 67% Elliptic Laboratories (OB:ELABS) 22.9% 79% Diamyd Medical (OM:DMYD B) 11.9% 93% CTT Systems (OM:CTT) 17.5% 34.2% Bonesupport Holding (OM:BONEX) 10.4% 56.1% Bergen Carbon Solutions (OB:BCS) 12% 63.2% Click here to see the full list of 213 stocks from our Fast Growing European Companies With High Insider Ownership screener. Here's a peek at a few of the choices from the screener. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Atea ASA delivers IT infrastructure and related solutions to businesses and public sector organizations across the Nordic countries and Baltic regions, with a market cap of NOK16.73 billion. Operations: The company's revenue is derived from its operations in various regions, including Norway (NOK9.00 billion), Sweden (NOK13.06 billion), Denmark (NOK8.25 billion), Finland (NOK3.57 billion), the Baltics (NOK1.80 billion), and Group Shared Services (NOK10.81 billion). Insider Ownership: 29.1% Atea ASA's revenue is projected to grow at 9.4% annually, outpacing the Norwegian market's 2.6% growth rate, while earnings are expected to rise by 19.7%. Despite trading at nearly 40% below estimated fair value, recent earnings showed a decline in net income and EPS compared to last year. The dividend yield of 4.66% isn't well covered by earnings but was affirmed for distribution in May and November 2025 as a capital repayment. Unlock comprehensive insights into our analysis of Atea stock in this growth report. Our expertly prepared valuation report Atea implies its share price may be lower than expected. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Hanza AB (publ) offers manufacturing solutions and has a market cap of SEK3.84 billion. Operations: The company's revenue segments include Main Markets at SEK2.92 billion, Other Markets at SEK2.06 billion, and Business Development and Services contributing SEK32 million. Insider Ownership: 34.8% Hanza AB's earnings are forecast to grow significantly at 28.1% annually, outpacing the Swedish market's 15.9%. Despite a lower net profit margin of 2.4% compared to last year's 4.4%, recent Q1 results showed sales of SEK 1.33 billion and net income of SEK 40 million, improving from last year. Insider buying has been substantial recently, indicating confidence in its growth prospects, while the stock trades at a discount to its estimated fair value. Take a closer look at Hanza's potential here in our earnings growth report. According our valuation report, there's an indication that Hanza's share price might be on the expensive side. Simply Wall St Growth Rating: ★★★★★☆ Overview: LEM Holding SA, along with its subsidiaries, offers solutions for measuring electrical parameters across various regions including China, Japan, South Korea, India, Southeast Asia, Europe, the Middle East, Africa, NAFTA and Latin America with a market cap of CHF894.82 million. Operations: The company's revenue is primarily derived from Asia, contributing CHF168.27 million, and Europe/Americas, which accounts for CHF138.66 million. Insider Ownership: 29.9% LEM Holding's earnings are forecast to grow significantly at 48% annually, surpassing the Swiss market's 10.7%. Despite a challenging year with sales dropping to CHF 306.92 million and net income falling sharply, the company trades at a discount of 24.5% below its estimated fair value. No substantial insider trading activity is noted recently, while revenue growth is expected to outpace the market at 9.7% annually, and Return on Equity is projected to reach a high level of 32.5%. Click to explore a detailed breakdown of our findings in LEM Holding's earnings growth report. Our valuation report here indicates LEM Holding may be undervalued. Click here to access our complete index of 213 Fast Growing European Companies With High Insider Ownership. Ready To Venture Into Other Investment Styles? Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years. Companies discussed in this article include OB:ATEA OM:HANZA and SWX:LEHN. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
4 days ago
- Business
- Yahoo
European Market Gems: Stocks Trading Below Estimated Value In June 2025
Amidst a backdrop of easing inflation and potential interest rate cuts by the European Central Bank, the European markets have shown resilience with indices like Germany's DAX and Italy's FTSE MIB posting gains. In such an environment, identifying stocks that are trading below their estimated value can present unique opportunities for investors seeking to capitalize on market inefficiencies. Name Current Price Fair Value (Est) Discount (Est) Micro Systemation (OM:MSAB B) SEK48.30 SEK95.13 49.2% CTT Systems (OM:CTT) SEK208.00 SEK406.70 48.9% Absolent Air Care Group (OM:ABSO) SEK211.00 SEK416.98 49.4% Sparebank 68° Nord (OB:SB68) NOK179.40 NOK358.38 49.9% USU Software (HMSE:OSP2) €25.485 €50.83 49.9% Vestas Wind Systems (CPSE:VWS) DKK106.20 DKK209.54 49.3% Montana Aerospace (SWX:AERO) CHF19.72 CHF38.66 49% doValue (BIT:DOV) €2.31 €4.50 48.7% 3U Holding (XTRA:UUU) €1.495 €2.99 49.9% VIGO Photonics (WSE:VGO) PLN526.00 PLN1024.74 48.7% Click here to see the full list of 182 stocks from our Undervalued European Stocks Based On Cash Flows screener. Let's explore several standout options from the results in the screener. Overview: Atea ASA offers IT infrastructure and related solutions to businesses and public sector organizations across the Nordic countries and Baltic regions, with a market cap of NOK16.73 billion. Operations: The company's revenue segments are comprised of NOK9 billion from Norway, NOK13.06 billion from Sweden, NOK8.25 billion from Denmark, NOK3.57 billion from Finland, and NOK1.80 billion from the Baltics, with Group Shared Services contributing an additional NOK10.81 billion. Estimated Discount To Fair Value: 39.7% Atea is trading at NOK 150.2, significantly below its estimated fair value of NOK 249, suggesting it may be undervalued based on cash flows. The company's revenue and earnings are forecast to grow faster than the Norwegian market, with earnings expected to rise by 19.7% annually. Despite a dividend yield of 4.66%, it's not well covered by earnings, raising sustainability concerns. Recent Q1 results showed increased sales but a decline in net income year-over-year. Our expertly prepared growth report on Atea implies its future financial outlook may be stronger than recent results. Take a closer look at Atea's balance sheet health here in our report. Overview: Hoist Finance AB (publ) is a credit market company involved in loan acquisition and management across Europe, with a market cap of SEK8.36 billion. Operations: The company's revenue segments consist of SEK1.16 billion from secured loans and SEK2.99 billion from unsecured loans. Estimated Discount To Fair Value: 19.6% Hoist Finance is trading at SEK 95.65, below its fair value estimate of SEK 119.04, reflecting potential undervaluation based on cash flows. While earnings grew by 34.6% last year and are forecast to grow significantly over the next three years, revenue growth is slower than ideal but still outpaces the Swedish market average. The company has a high debt level and a recent dividend approval of SEK 2 per share, though its dividend track record remains unstable. Our earnings growth report unveils the potential for significant increases in Hoist Finance's future results. Unlock comprehensive insights into our analysis of Hoist Finance stock in this financial health report. Overview: LEM Holding SA, along with its subsidiaries, offers solutions for measuring electrical parameters across various regions including China, Japan, South Korea, India, Southeast Asia, Europe, the Middle East, Africa, NAFTA and Latin America; the company has a market cap of CHF894.82 million. Operations: The company's revenue is primarily derived from two segments: Asia, contributing CHF168.27 million, and Europe/Americas, contributing CHF138.66 million. Estimated Discount To Fair Value: 24.5% LEM Holding is trading at CHF 786, below its estimated fair value of CHF 1040.42, suggesting undervaluation based on cash flows. Despite a challenging year with net income dropping to CHF 8.39 million from CHF 65.33 million, earnings are forecast to grow significantly at 48% annually over the next three years, outpacing the Swiss market average. However, profit margins have decreased and the company carries a high level of debt. Upon reviewing our latest growth report, LEM Holding's projected financial performance appears quite optimistic. Click here to discover the nuances of LEM Holding with our detailed financial health report. Access the full spectrum of 182 Undervalued European Stocks Based On Cash Flows by clicking on this link. Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools. Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include OB:ATEA OM:HOFI and SWX:LEHN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12-05-2025
- Business
- Yahoo
Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
Enrollment Ongoing in Phase 3 C-BEYOND Trial for Treatment of HCV Full Phase 2 Results for Regimen of Bemnifosbuvir and Ruzasvir for HCV and Results from Three Additional Phase 1 Studies Supporting Potential Best-in-Class Profile Presented at European Association for the Study of the Liver (EASL) Congress 2025 Virtual Investor Event with Key Opinion Leader Insights on HCV to be Held May 14, 2025, at 10:00 AM ET BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the first quarter ended March 31, 2025 and provided a business update. The Company's combination regimen of bemnifosbuvir (BEM), a nucleotide analog polymerase inhibitor, and ruzasvir (RZR), an NS5A inhibitor, is in Phase 3 development for the treatment of hepatitis C virus (HCV). 'Atea has made very significant progress thus far in 2025, initiating and continuing to enroll patients in C-BEYOND, our Phase 3 clinical trial evaluating the regimen of bemnifosbuvir and ruzasvir for the treatment of HCV in the US and Canada,' said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea. 'We are also focused on initiating our second Phase 3 trial, C-FORWARD, which will be conducted at clinical sites outside of North America. We expect enrollment of patients in C-FORWARD to begin mid-year.' "We are very encouraged by the positive results of the Phase 2 clinical study and additional data presented at EASL 2025 supporting the efficacy, safety and potential best-in-class profile of our regimen of bemnifosbuvir and ruzasvir, including short treatment duration, low risk for drug-drug interactions, and convenience with no food effect,' continued Dr. Sommadossi. 'We believe our regimen, if approved, has the potential to increase the number of treated and cured HCV patients and to disrupt the global HCV market of approximately $3 billion in net sales." HCV KOL Investor Event to be Held May 14, 2025 at 10:00 AM ET Atea will host a virtual key opinion leader (KOL) investor event with a panel of HCV experts and prescribers on Wednesday, May 14, 2025, at 10:00 AM ET. To register, click here. This KOL event will replace Atea's first quarter 2025 earnings conference call, and Quarterly calls will resume with the second quarter 2025 financial results. This investor event will include an expert panel of several leaders in hepatology, gastroenterology, infectious diseases, and HCV treatments in the US, Canada and Europe. These experts and prescribers will discuss the current challenges experienced by people living with HCV, the full results of Atea's global Phase 2 study evaluating the regimen of BEM/RZR for the treatment of HCV, and what a new optimized HCV therapy could provide for prescribers and patients. Company management will discuss the HCV commercial market opportunity and the ongoing global Phase 3 clinical development. Summary of Results Presented at EASL Poster Title: Efficacy and Safety of Bemnifosbuvir and Ruzasvir after 8 Weeks of Treatment in Patients with Chronic Hepatitis C Virus (HCV) Infection (TOP-251)Conclusion: The Phase 2 study results demonstrated that an 8-week combination regimen of BEM (550 mg) and RZR (180 mg) achieved SVR12 in 98% of treatment-adherent patients and 95% of patients regardless of treatment adherence. The regimen was safe and well-tolerated with low rates of virologic failure and no study-drug-related serious adverse events or treatment discontinuations. Treatment emergent adverse events (TEAEs) were reported in 43% (118/275) of patients. Most TEAEs were mild to moderate in intensity, with headache (9%) and nausea (8%) being the most reported. These results reinforce the potential of the combination regimen of BEM and RZR as a best-in-class treatment for Title: Pharmacokinetics of Bemnifosbuvir in Participants with Hepatic Impairment (WED-278)Conclusion: A Phase 1 pharmacokinetic study evaluating a single 550 mg dose of BEM in participants with varying degrees of hepatic impairment showed increased drug exposure in individuals with moderate to severe liver dysfunction. However, these changes did not meaningfully affect levels of AT-273, the plasma marker for the active intracellular antiviral metabolite of BEM. No safety concerns were identified. These results support the use of BEM without dose adjustment in patients with hepatic impairment. Poster Title: No DDI Between Bemnifosbuvir/Ruzasvir and Bictegravir/Emtricitabine/Tenofovir Alafenamide (WED-279)Conclusion: Findings from a Phase 1 drug-drug interaction study in healthy participants demonstrated that co-administration of BEM/RZR with the standard human immunodeficiency virus (HIV) regimen bictegravir/emtricitabine/tenofovir alafenamide (B/FTC/TAF) resulted in no clinically significant pharmacokinetic changes. The co-administered HCV/HIV combinations were generally safe and well tolerated. These results support the future inclusion of HCV/HIV co-infected patients receiving these HIV therapies in the Phase 3 clinical development program for BEM/RZR. It is estimated that in the US as many as 6 to 30% of HCV patients are co-infected with HIV.1 Poster Title: Pharmacokinetics of Bemnifosbuvir in Participants with Renal Impairment (WED-280)Conclusion: A Phase 1 renal impairment study showed that a single 550 mg dose of BEM was safe and well-tolerated across participants with normal kidney function, moderate-to-severe renal impairment, and those with end-stage renal disease on hemodialysis. While the circulating inactive nucleoside metabolites of BEM increased as expected in renally impaired individuals, exposure of BEM remained consistent. These findings suggest that BEM may be used without dose adjustment in patients with renal dysfunction, including those undergoing dialysis. About the Bemnifosbuvir / Ruzasvir HCV Phase 3 Program Atea's HCV Phase 3 program includes two open-label Phase 3 trials, C-BEYOND in the US and Canada, and C-FORWARD, a global trial outside of North America. Each Phase 3 trial will enroll approximately 880 treatment-naïve patients, including those with and without compensated cirrhosis. The trials will compare the fixed-dose combination (FDC) regimen of BEM/RZR to the FDC regimen of sofosbuvir and velpatasvir. The regimen of BEM/RZR will be administered orally once-daily for eight weeks (in patients without cirrhosis) or 12 weeks (in patients with compensated cirrhosis) while the regimen of sofosbuvir and velpatasvir will be administered orally once-daily for 12 weeks to all patients, with or without compensated cirrhosis. The primary endpoint for each trial is HCV RNA < lower limit of quantitation (LLOQ) at 24 weeks from the start of treatment and encompasses sustained virologic response 12 weeks post-treatment (SVR12) in each arm. Measurement at 24 weeks from the start of treatment is to ensure the primary endpoint occurs at the same relative timepoint from the start of treatment in all patients. Patient enrollment in the C-BEYOND trial is ongoing and enrollment in the C-FORWARD trial is expected to begin in mid-2025. The initiation of the Phase 3 program follows a successful engagement with the US Food and Drug Administration (FDA) at an End-of-Phase 2 meeting in January 2025, shortly after the Company announced the topline results from the Phase 2 study evaluating the potential best-in-class regimen of BEM/RZR, including data demonstrating that the regimen met its primary endpoints of efficacy (SVR12) and safety. Business and Organizational Updates In December 2024, Atea engaged Evercore, a global independent investment bank, to identify potential opportunities to enhance shareholder value. The process includes a review of a broad range of strategic alternatives, including strategic partnerships, acquisition, merger, or other business combination, sale of assets or other strategic transactions. The process is ongoing, and the Company continues to evaluate all options to maximize shareholder value. In the first quarter 2025, to enhance efficiency in the management of infrastructure expenditures, Atea reduced its workforce by approximately 25%. This workforce reduction is expected to result in cost savings of approximately $15 million through 2027. In February 2025, Arthur S. Kirsch was appointed to the Company's Board of Directors. Mr. Kirsch has extensive knowledge of the healthcare and life sciences industries gained from decades of investment banking and capital markets experience as well as extensive public board and strategic experience. In April 2025, Atea further refreshed its Board of Directors with the appointment of Howard H. Berman, PhD. The appointment of Dr. Berman, who is currently serving as an observer, will become effective upon the completion of Atea's 2025 Annual Meeting of Stockholders. Dr. Berman has over 20 years of entrepreneurial and life science industry experience working at the interplay of science and business. In April 2025, Atea announced that its Board had authorized the repurchase of up to $25 million of the Company's common stock. This authorization reflects the Company's commitment to return capital to shareholders, while maintaining the capacity to complete its global Phase 3 HCV program and position Atea for long-term success. First Quarter 2025 Financial Results Cash, Cash Equivalents and Marketable Securities: $425.4 million at March 31, 2025, compared to $454.7 million at December 31, 2024. Research and Development Expenses: Research and development expenses decreased by $28.0 million from $57.6 million for the three months ended March 31, 2024, to $29.6 million for the three months ended March 31, 2025. The net decrease was primarily driven by lower external spend as Atea's COVID-19 Phase 3 SUNRISE-3 clinical trial was completed in 2024. The decrease was offset by an increase in external spend principally related to startup activities for the Company's HCV Phase 3 clinical development. Additionally, a decrease in internal research and development expenses was primarily related to lower stock-based compensation expense in the three-month period ended March 31, 2025. General and Administrative Expenses: General and administrative expenses decreased by $2.8 million from $12.2 million for the three months ended March 31, 2024, to $9.5 million for the three months ended March 31, 2025. The net decrease was primarily related to lower stock-based compensation expense, partially offset by increased professional Income and Other, Net: Interest income and other, net, decreased by $1.9 million for the three months ended March 31, 2025, compared to the three months ended March 31, 2024, primarily due to lower investment balances. Income Taxes: Income tax expense was $0.2 million for the three months ended March 31, 2025, and March 31, 2024. Condensed Consolidated Statement of Operations and Comprehensive Loss(in thousands, except share and per share amounts)(unaudited) Three Months EndedMarch 31, 2025 2024 Operating expenses Research and development $ 29,584 $ 57,575 General and administrative 9,457 12,231 Total operating expenses 39,041 69,806 Loss from operations (39,041 ) (69,806 ) Interest income and other, net 4,972 6,868 Loss before income taxes (34,069 ) (62,938 ) Income tax expense (203 ) (231 ) Net loss $ (34,272 ) $ (63,169 ) Other comprehensive loss Unrealized loss on available-for-sale investments (115 ) (388 ) Comprehensive loss $ (34,387 ) $ (63,557 ) Net loss per share - basic and diluted $ (0.40 ) $ (0.75 ) Weighted-average number of common shares - basic and diluted 85,159,254 83,916,193 Selected Condensed Consolidated Balance Sheet Data(in thousands)(unaudited) March 31, 2025 December 31, 2024 Cash, cash equivalents and marketable securities $ 425,436 $ 454,721 Working capital(1) 411,961 443,752 Total assets 439,964 464,668 Total liabilities 28,880 25,801 Total stockholder's equity 411,084 438,867 (1 ) Atea defines working capital as current assets less current liabilities. See the Company's condensed consolidated financial statements in its Quarterly Report on Form 10-Q for the three months ended March 31, 2025, for further detail regarding its current assets and liabilities. About HCV HCV is a blood-borne, positive-sense, single-stranded (ss) RNA virus that primarily infects liver cells. HCV is a leading cause of chronic liver disease and liver transplants, spreading via blood transfusion, hemodialysis and needle sticks, with approximately 240,000 deaths occurring each year. Despite the availability of direct-acting antivirals, HCV continues to be a significant global healthcare issue. An estimated 50 million people worldwide are chronically infected with HCV and there are approximately one million new infections each year. In the US, between 2.4 and 4 million people are estimated to have HCV with annual new infections outpacing treatment rates. HCV infections in the US predominate in patients in the age group between 20-49 years old, and it is estimated that less than 10% of HCV-infected patients in the US have cirrhosis. Chronic HCV infection is the leading cause of liver cancer in the US, Europe and Japan. About Atea Pharmaceuticals Atea is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. Leveraging Atea's deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases. Atea plans to continue to build its pipeline of antiviral product candidates by augmenting its nucleos(t)ide platform with other classes of antivirals that may be used in combination with its nucleos(t)ide product candidates. Atea's lead program and current focus is on the development of the combination of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, to treat HCV. For more information, please visit Forward-Looking Statements This press release includes 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include but are not limited to statements regarding the potential best-in-class profile of the regimen of BEM and RZR for the treatment of HCV, the potential opportunity created by the regimen to increase the number of patients treated and cured, the opportunity to disrupt the global HCV market, the expected time of commencement of enrollment in the C-FORWARD Phase 3 clinical trial, future results of operations and financial position, business strategy, anticipated milestone events and timelines for clinical trials, benefits of cost savings initiatives, repurchases under the Company's share repurchase program, the timing and outcome of the Company's strategic alternatives review, the timing and agenda of the Company's KOL event and the Company's plans to resume Quarterly earnings calls in the second quarter of 2025. When used herein, words including 'expected,' 'should,' 'anticipated,' 'believe.' 'will,' 'plans', and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Atea's current expectations and various assumptions. Atea believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Atea may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, uncertainties inherent in the drug discovery and development process and the regulatory submission or approval process, unexpected or unfavorable safety or efficacy data or results observed during clinical trials or in data readouts; delays in or disruptions to clinical trials or our business; our reliance on third parties over which we may not always have full control, our ability to manufacture sufficient commercial product, competition from approved treatments for HCV, the timeline for the completion of the strategic alternatives review process is unknown and there can be no assurance that the process will result in any particular outcome; dependence on the success of Atea's most advanced product candidates, in particular the combination of BEM and RZR for the treatment of HCV; as well as the other important factors discussed under the caption 'Risk Factors' in Atea's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SEC's website at These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While Atea may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing Atea's views as of any date subsequent to the date of this press release. Contacts Jonae BarnesSVP, Investor Relations and Corporate Joyce AllaireLifeSci Advisorsjallaire@ 1
Yahoo
10-04-2025
- Business
- Yahoo
European Dividend Stocks Yielding Up To 6.2%
As European markets grapple with the impact of higher-than-expected U.S. trade tariffs, major indices like the STOXX Europe 600 and Germany's DAX have experienced significant declines, reflecting broader concerns about economic growth and inflation. In such uncertain times, dividend stocks can offer a measure of stability and income potential, making them an attractive option for investors seeking to navigate volatile market conditions. Name Dividend Yield Dividend Rating Julius Bär Gruppe (SWX:BAER) 5.52% ★★★★★★ Bredband2 i Skandinavien (OM:BRE2) 5.25% ★★★★★★ Zurich Insurance Group (SWX:ZURN) 4.94% ★★★★★★ Mapfre (BME:MAP) 6.15% ★★★★★★ HEXPOL (OM:HPOL B) 5.35% ★★★★★★ Allianz (XTRA:ALV) 4.89% ★★★★★★ Deutsche Post (XTRA:DHL) 5.67% ★★★★★★ Cembra Money Bank (SWX:CMBN) 4.56% ★★★★★★ Rubis (ENXTPA:RUI) 8.90% ★★★★★★ Banque Cantonale Vaudoise (SWX:BCVN) 4.76% ★★★★★★ Click here to see the full list of 247 stocks from our Top European Dividend Stocks screener. We'll examine a selection from our screener results. Simply Wall St Dividend Rating: ★★★★☆☆ Overview: Atea ASA offers IT infrastructure and related solutions for businesses and public sector organizations in the Nordic countries and Baltic regions, with a market cap of NOK14.03 billion. Operations: Atea ASA generates revenue from several segments, including Norway (NOK8.80 billion), Sweden (NOK12.76 billion), Denmark (NOK7.86 billion), Finland (NOK3.58 billion), and The Baltics (NOK1.72 billion). Dividend Yield: 5.6% Atea's dividend payments, covered by a low cash payout ratio of 48.7%, have been stable and growing over the past decade, reflecting reliability. However, with a high payout ratio of 101.2%, dividends are not well covered by earnings, raising sustainability concerns. Despite trading at 45.9% below estimated fair value, Atea's dividend yield of 5.56% is modest compared to top Norwegian payers and recent earnings show slight declines in net income and EPS year-over-year. Delve into the full analysis dividend report here for a deeper understanding of Atea. Our valuation report unveils the possibility Atea's shares may be trading at a discount. Simply Wall St Dividend Rating: ★★★★☆☆ Overview: Burkhalter Holding AG, with a market cap of CHF1.11 billion, operates through its subsidiaries to deliver electrical engineering services to the construction sector mainly in Switzerland. Operations: Burkhalter Holding AG generates revenue of CHF1.18 billion from its electrical engineering services primarily serving the construction sector in Switzerland. Dividend Yield: 4.3% Burkhalter Holding's dividend yield of 4.27% ranks in the top quartile among Swiss dividend payers, yet its dividends have been unreliable and volatile over the past decade. Despite a high payout ratio of 87.4%, indicating coverage by earnings, insufficient data on cash flow coverage raises sustainability concerns. The company faces financial challenges with high debt levels but has shown robust earnings growth averaging 26.2% annually over five years, suggesting potential for future stability. Click here and access our complete dividend analysis report to understand the dynamics of Burkhalter Holding. Upon reviewing our latest valuation report, Burkhalter Holding's share price might be too optimistic. Simply Wall St Dividend Rating: ★★★★☆☆ Overview: WashTec AG offers car wash solutions across Germany, Europe, North America, and the Asia Pacific with a market cap of €517.90 million. Operations: WashTec AG's revenue is primarily derived from its operations in Europe and Other regions, which account for €394.74 million, followed by North America contributing €85.20 million. Dividend Yield: 6.2% WashTec's dividend yield of 6.2% places it among the top German dividend payers, but sustainability concerns arise due to a high payout ratio of 103.5%, not covered by earnings. Despite this, dividends have increased over the past decade, although they've been volatile. Recent earnings showed improved net income at €31.03 million with guidance indicating revenue and EBIT growth in 2025, suggesting potential for future financial stability despite current challenges in dividend reliability. Unlock comprehensive insights into our analysis of WashTec stock in this dividend report. Our expertly prepared valuation report WashTec implies its share price may be lower than expected. Gain an insight into the universe of 247 Top European Dividend Stocks by clicking here. Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments. Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include OB:ATEA SWX:BRKN and XTRA:WSU. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
